Wolfe Research Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to “Strong-Buy”

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

ASND has been the topic of a number of other research reports. Stifel Nicolaus raised their price target on Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Raymond James Financial assumed coverage on shares of Ascendis Pharma A/S in a research note on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Citigroup restated a “buy” rating and issued a $290.00 target price (up from $243.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $256.60.

Ascendis Pharma A/S Trading Down 2.3%

Shares of ASND stock opened at $212.15 on Monday. The stock has a market cap of $13.09 billion, a P/E ratio of -41.11 and a beta of 0.44. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $223.18. The stock has a 50 day simple moving average of $202.65 and a 200 day simple moving average of $185.66.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The business had revenue of $290.24 million during the quarter, compared to analysts’ expectations of $246.91 million. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $26,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Ascendis Pharma A/S during the second quarter worth $39,000. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after buying an additional 83 shares in the last quarter. First Horizon Advisors Inc. bought a new position in shares of Ascendis Pharma A/S in the 2nd quarter valued at $41,000. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 262 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.